Dr. Paul Adams joins La Jolla Pharmaceutical advisory board

La Jolla Pharmaceutical Company has named four physicians to its LJPC-401 advisory board, including gastroenterologist Paul Adams, MD.  

Advertisement

The LJPC-401 advisory board focuses on the company’s development of hepcidin. Dr. Adams is a professor of medicine and chief of gastroenterology at the University of Western Ontario in London, Ontario. The company also added:

•    Victor Gordeuk, MD
•    Ashutosh Lal, MD
•    Gordon McLaren, MD

More articles on gastroenterology:
Mutare Health names Dr. Lawrence Kosinski CMO
Ritter Pharmaceuticals names Gerald Proehl to board of directors
PPI therapy may increase risk of kidney injury in elderly

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • GI Partners of Illinois, the largest independent physician-led gastroenterology group in the state, has announced a strategic partnership with Nexus…

  • Colonoscopies are booming, but the economics are getting complicated.  As colorectal cancer rates climb and updated screening guidelines add millions…

Advertisement

Comments are closed.